MedTrace Logo

A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.

NCT02585596 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2019-01-16

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and the safety of YH23537 in Korea patients with chronic periodontitis, in order to investigate the recommended therapeutic dose.

Conditions

  • Chronic Periodontitis

Interventions

DRUG

YH23537 1000mg/day

YH23537 500mg 2 tab

DRUG

YH23537 2000mg/day

YH23537 500mg 4 tab

DRUG

YH23537 3000mg/day

YH23537 500mg 6 tab

DRUG

placebo

YH23537 500mg tab placebo

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Incheol Rhyu, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-16
Primary Completion
2016-12-28
Completion
2017-06-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585596 on ClinicalTrials.gov